摘要
目的:探讨多药耐药基因-1(MDR-1)表达产物P-糖蛋白(P-gp)在鼻腔、鼻咽部恶性淋巴瘤组织中表达的临床意义。方法:用S-P免疫组化染色方法,检测37例鼻腔、鼻咽部恶性淋巴瘤组织中P-gp表达情况,并与患者的初诊与复诊、原发部位、病理类型、免疫组化分型等不同组织中P-gp的表达及预后相关性进行分析。结果:P-gp表达阳性的是复诊患者87.5%(7/ 8)、鼻咽部患者70.0%(7/10),与初诊患者34.5%(10/29)、鼻腔部患者37.0%(10/27)相比,均有明显差异;P-gp阳性表达患者耐药率88.2%(15/17),与P-gp阴性表达患者耐药率10.0%(2/20)相比,有明显差异。结论:P-gp阳性表达对预测耐药及临床医师选药、制定方案提供科学依据。
OBJECTIVE: To discuss the clinical significance of the expression of P-glycoprotein (P-gp), the multidrug resistance gene- 1 (MDR- 1) expression product in the malignant lymphoma of nasalcavity and pharynx nasalis. METHODS: The expression of P - gp in the malignancy lymphoma of nasalcavity and pharynx nasalis of 37 cases was detected by S - P Immunohistochemical staining, and its correlations with patents' first visit, return visit, original sites, pathological type, immunohistochemical typing and prognosis were analyzed. RESULTS: Positive P- gp expression appeared in 87.5% (7/8) of the patients for return visit vs. 34.5% (10/29) for first visit and 70.0% (7/10) with malignant lymphoma at pharynx nasalis vs. 37.0% (10/27) with malignant lymphoma at nasal cavity, all showing significant differences. There were also significant differences in drug resistance between the patients with positive P- gp expression and those with negative P gp expression (88.2% (15/17) vs. 10.0% (2/20)) . CONCLUSION: Positive P-gp expression serves as scientific basis for clinicians in predicating drug resistance and selecting drugs and establishing schemes.
出处
《中国药房》
CAS
CSCD
北大核心
2009年第11期843-845,共3页
China Pharmacy
关键词
P-糖蛋白
多药耐药基因-1
鼻腔
鼻咽部恶性淋巴瘤
S—P免疫组化
耐药性
P - glycoprotein
Multidrug resistance gene - 1
Malignancy lymphoma in nasalcavity and pharynx nasalis
S P Imrnunohistochemistry
Drug resistance